Full-Time

Director – Regulatory Affairs Labeling

Posted on 1/16/2025

Pliant Therapeutics

Pliant Therapeutics

51-200 employees

Develops treatments for fibrotic diseases

Compensation Overview

$225k - $235kAnnually

+ Equity + Annual Target Bonus

Senior, Expert

San Bruno, CA, USA

This is a hybrid position requiring 3 days/week at Pliant in South San Francisco.

Category
Risk & Compliance
Legal & Compliance
Requirements
  • BS degree in scientific, clinical or related area required
  • Advanced degree highly desirable
  • Regulatory Affairs certification strongly preferred
  • 12 years pharmaceutical/biotechnology industry experience with a minimum of 8 years in Regulatory Affairs
  • Proven track record of successful submissions to FDA and in-depth working knowledge of labeling
  • Excellent leadership skills with ability to lead and influence cross functional teams focused on attaining company goals
  • Ensure labeling is compliant with applicable regulations (e.g., FDA, EU MDR, ISO standards) and internal quality standards
  • Strong technical writing and documentation skills
  • Expertise in interpreting regulations, guidelines, policy statements, including comprehensive knowledge of applicable regulations with demonstrated knowledge relevant to labeling
  • Proven ability to foster effective, positive interactions with regulatory agencies and corporate partners and to effectively interface with the senior management team and regulatory agencies
  • Adaptability with small company lean-resourced mindset for effectively working with peers, which includes hands-on experience drafting regulatory documents and submissions with practical experience relevant to labeling
  • Well organized with exceptional communication skills, strong influencing skills, and a demonstrated ability to use constructive debate to identify and move others towards optimal outcomes.
Responsibilities
  • Lead the development, revision, review, approval, and maintenance of primary labeling (the Company Core Data Sheet (CCDS), United States Package Insert (USPI) and associated patient labeling, EU Product Information (EUPI)), and derived documents (labeling text for EU, US) for assigned compounds.
  • Give strategic direction, sound recommendations and guidance about labeling content, processes, timelines, and scientific integrity. Coordinate the resolution of any labeling issues with potential impact on the primary or derived labeling, or the supporting documentation. Ensure high quality and compliant labeling documents.
  • Provide strategic guidance regarding new and revised labeling regulations, competitor labeling, and labeling trends.
  • Exhibit a strong understanding of competitors in the therapeutic area and their development plans and status and knowledge of labeling aspects for the development of labeling and target labeling.
  • Coordinate project timelines, set milestones, and monitor progress to ensure labeling projects meet established deadlines.
  • Support training initiatives by developing and delivering training materials related to labeling
  • Prioritize the continuous improvement of the end-to-end labeling process.
  • Demonstrate an understanding of broad concepts within regulatory affairs and implications across organization. Proactively identifies labeling issues and offers creative solutions and strategies, including risk mitigation strategies.
  • Keeps up to date on emerging clinical, product safety, and post-marketing data that may trigger changes to the company core datasheet and labeling.
  • Manage labeling negotiations and drafts responses to Health Authorities queries. Guides/supports all labeling related negotiation meetings or teleconferences, as needed.
  • Proactively recognize and take ownership of new labeling assignments, assessing project requirements and aligning resources.
  • Track and manage health authority labeling requests and responses.
  • Lead the development of labeling policies, procedures and SOPs.

Pliant Therapeutics develops treatments for fibrotic diseases, which cause thickening and scarring of connective tissue, leading to organ dysfunction. Their products work by targeting the biological mechanisms behind fibrosis, particularly through the inhibition of integrins, proteins that help cells adhere and communicate. This focus allows Pliant to create specific and effective therapies for various fibrotic conditions. Unlike competitors, Pliant emphasizes a deep understanding of fibrosis and integrin biology, which informs their drug development process. The company's goal is to halt the progression of fibrotic diseases and restore normal organ function, ultimately improving the lives of patients affected by these conditions.

Company Size

51-200

Company Stage

IPO

Headquarters

San Francisco, California

Founded

2015

Simplify Jobs

Simplify's Take

What believers are saying

  • Positive Phase 2a trial data for bexotegrast in PSC boosts clinical confidence.
  • FDA's fast-tracking of orphan drugs supports Pliant's pipeline advancement.
  • Growing interest in integrin inhibitors aligns with Pliant's strategic focus.

What critics are saying

  • Ongoing securities investigation may impact investor confidence and stock value.
  • Accelerated bexotegrast development could strain finances if trials fail.
  • New executive appointments may disrupt current operations or delay projects.

What makes Pliant Therapeutics unique

  • Pliant focuses on integrin inhibitors for fibrotic diseases, a unique therapeutic approach.
  • PLN-74809 targets IPF and PSC, both with Orphan Drug Designation from the FDA.
  • Partnership with Novartis for PLN-1474 enhances credibility and development capabilities.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Company Match

Remote Work Options

Flexible Work Hours

Professional Development Budget

Wellness Program

Mental Health Support

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Paid Vacation

Paid Sick Leave

Paid Holidays

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Employee Stock Purchase Plan

Performance Bonus

Relocation Assistance

Employee Referral Bonus

Student Loan Assistance

Adoption Assistance

Childcare Support

Elder Care Support

Pet Insurance

Bereavement Leave

Commuter Benefits

Meal Benefits

Legal Services

Employee Discounts

Company Social Events

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

0%

2 year growth

7%
Markets Gone Wild
Feb 25th, 2025
Pomerantz Law Firm Investigates Potential Securities Claims Against Pliant Therapeutics, Inc. (PLRX): What You Need to Know

The investigation concerns whether Pliant and certain of its officers and directors have made false and/or misleading statements and/or failed to disclose material information in violation of the securities exchange act of 1934 (the "exchange act").

European Governments Today
Oct 1st, 2024
Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs

Pliant Therapeutics appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs.

GlobeNewswire
Jun 13th, 2024
Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors

Pliant Therapeutics announces appointment of Steve Krognes to Board of Directors.

Pulmonary Fibrosis News
Apr 5th, 2024
Pliant Therapeutics accelerates development of bexotegrast for IPF

In 2023, Pliant launched the BEACON-IPF (NCT06097260) study as a Phase 2b trial with the goal of recruiting about 270 IPF patients, ages 40 and older, at clinical sites across the globe.

Xconomy
Mar 7th, 2024
Home | Informa Connect

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

INACTIVE